deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT00738595

Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.

Phase II Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation, Effect on it Own and in Combination With Open Label Nicotine Replacement Therapy.

Sponsor: Clinpharm International Management Holding GmbH

Conditions Smoking Cessation
Interventions EVT 302 EVT 302 plus open label Nicotine replacement Placebo Placebo plus open label Nicotine Replacement
Updated 8 times since 2017 Last updated: May 28, 2009 Started: Aug 31, 2008 Primary completion: Mar 31, 2009 Completion: May 31, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Smoking Cessation, this trial is completed. The trial is conducted by Clinpharm International Management Holding GmbH and has accumulated 8 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotCompleted~Oct 2021 – ~Jul 2024 · 33 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Oct 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Clinpharm International Management Holding GmbH
  • Evotec Neurosciences GmbH
  • PRA Health Sciences
Data source: Evotec International GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations